Eye Layer Thinning and a Nerve Blood Marker in Multiple Sclerosis on Ofatumumab
Studies eye layer thinning in adults with relapsing multiple sclerosis taking ofatumumab.
Plain-language title generated from the registry record
Registry title: Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
Key facts
- Where
- Baltimore, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06167642, who can take part
Where in United States
- Johns HopkinsBaltimore, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT06167642
- Record updated
- 10 June 2026
- Original description
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.Read full original descriptionShow less
Assessing the Modulation of Retinal Atrophy and Neurofilament Light Chain by Ofatumumab in Relapsing Multiple Sclerosis
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.
Inclusion: Between 18 - 70 years of age; Have RMS as confirmed by the treating neurologist based on the 2017 revised McDonald criteria; AND Either; be due to commence ofatumumab within 60 days of baseline OCT/VA/phlebotomy or; be existing patients attending the center and already receiving ofatumumab, be eligible for inclusion, and already undergoing all of the proposed study procedures; Willing to sign informed consent; Willing to undergo phlebotomy.
Exclusion: Uncontrolled Diabetes; Uncontrolled Hypertension; Other neurologic or ophthalmologic disorders; Glaucoma; Refractive errors of +/- 6 diopters.